ZD 7155

Drug Profile

ZD 7155

Alternative Names: ICI D 7155

Latest Information Update: 06 Sep 2000

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antihypertensives; Heart failure therapies; Naphthyridines; Vasodilators
  • Mechanism of Action Angiotensin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic neuropathies; Hypertension

Most Recent Events

  • 06 Sep 2000 Discontinued-Preclinical for Diabetic neuropathies in United Kingdom (Unknown route)
  • 01 Jun 1995 Discontinued-Preclinical for Hypertension in United Kingdom (PO)
  • 28 Apr 1995 A study in animals has been added to the Hypertension pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top